Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03755102 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
A Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT03755102: Completed Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03755102 is a Early Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03755102, a Early Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.
Interventions
- DRUG Osimertinib
- DRUG Dacomitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2018-11-21 |
| Est. Completion | 2023-07-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03755102
The ClinicalTrials.gov registry entry for NCT03755102 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Osimertinib is the first listed.
NCT03755102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03755102 about?
NCT03755102 is a clinical study titled "A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.". The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.
What is the current status of trial NCT03755102?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2018-11-21. Estimated completion is 2023-07-07.
What interventions are being tested in trial NCT03755102?
The interventions under investigation include: Osimertinib (DRUG), Dacomitinib (DRUG).
Who is sponsoring clinical trial NCT03755102?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.